Pharmacokinetics of Psychedelics: New Insights from Systematic Review

Introduction to Psychedelic Pharmacokinetics

A recent systematic review published on May 29, 2026, in an unknown Tier 1 venue, provides an in-depth analysis of the pharmacokinetic properties of classical serotonergic psychedelics. This review, accessible through OpenAlex, focuses on lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), mescaline, and 5-methoxy-N,N-dimethyltryptamine (5-MEO-DMT).

The study collated data from 32 eligible trials involving healthy adult volunteers, aiming to bridge the knowledge gap in how these substances are absorbed, distributed, and eliminated in the body. Understanding these pharmacokinetic profiles is critical for optimizing dosing regimens and improving safety in clinical settings.

Mechanisms and Context

The review highlights that LSD was the most studied compound, followed by DMT, which was examined in both intravenous (IV) and oral formulations. Psilocybin also received significant attention, whereas mescaline was reported in only two trials. Notably, the study identified dose-proportional maximum concentration (Cmax) values for LSD and psilocybin.

Differences between oral and IV formulations of DMT were noted as potentially clinically significant, suggesting that the route of administration plays a crucial role in the pharmacokinetic behavior of these compounds. These findings are essential for researchers and clinicians aiming to develop effective and safe therapeutic protocols.

Implications for Research and Policy

The insights gained from this systematic review are poised to guide future research and clinical trials. By understanding the pharmacokinetic profiles of these substances, researchers can better determine the most effective and safe routes of administration, which is vital for the development of therapeutic applications.

For policy makers, these findings underscore the need for continued support of psychedelic research, particularly in optimizing dosing regimens that maximize therapeutic benefits while minimizing risks. Regulatory agencies may also use this information to refine guidelines for clinical trials involving psychedelics.

Risks and Unknowns

Despite the positive sentiment surrounding the review's findings, several risks and unknowns persist. The variability in pharmacokinetic profiles between different formulations and compounds suggests that more research is needed to fully understand their implications in diverse populations.

Additionally, the limited number of studies on certain compounds, such as mescaline and 5-MEO-DMT, highlights the need for further investigation into their pharmacokinetics. This gap in knowledge could impact the development of standardized dosing protocols and safety measures.

Looking Forward

As the field of psychedelic research continues to evolve, the insights from this systematic review will play a crucial role in shaping future studies and clinical applications. Researchers are encouraged to build upon these findings, exploring the nuances of psychedelic pharmacokinetics across different populations and settings.

Ultimately, a deeper understanding of these compounds' pharmacokinetic properties will enhance their therapeutic potential, paving the way for innovative treatments in mental health and beyond.